Monitor for near-term catalysts such as pipeline updates or partnership announcements that may have motivated the insider buying. The selling by legal and commercial officers is likely liquidity-driven and does not offset the CEO's signal.
KURA drugs
KURA drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Aug 25 $13.59entry
- T+1 · 3mo ago −3.90%α −3.92% · $13.06
- T+5 · 3mo ago −5.15%α −4.61% · $12.89
- T+20 · 8w ago −18.76%α −19.01% · $11.04
- T+58 · todayOpen
- T+60 · tomorrow Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kura Oncology CEO Troy Wilson purchased $1.24M in open-market shares at ~$12.39, while the Chief Legal Officer and Chief Commercial Officer sold a combined ~$449K. The CEO's buy is a strong bullish signal at ~0.11% of market cap, partially offset by routine insider selling from non-C-suite officers. The cluster is mixed in net direction but the CEO's conviction purchase dominates in both dollar value and seniority.
Key Financial Metrics
Key Facts
- CEO Troy Wilson purchased 100,000 shares for $1.24M in open-market transaction at $12.39/share
- Chief Legal Officer Teresa Bair sold 31,487 shares for $398K at $12.63
- Chief Commercial Officer Brian Powl sold 4,345 shares for $52K at $11.89
- Total insider cluster value: $1.69M ($1.24M buys, $449K sells)
- CEO buy represents ~0.11% of KURA's $1.1B market cap
Financial Impact
CEO purchase of $1.24M is material relative to typical insider activity; selling by two officers totals $449K, which is routine for a $1.1B market cap company
Risk Factors
- Insider selling by two senior officers could indicate internal concerns about near-term valuation
- Biotech sector volatility could overshadow insider signal
- CEO purchase at $12.39 is below recent levels; stock could face resistance
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-KURA-1787645134838 |
Track record
29 reports on KURA
6 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +52.28% at T+60 after the Jun 3, 2026 report. 10 of 13 went positive at some point.
Filters
- Nov 16, 2026today Insider Buy Bullish 5/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 16, 2026today 144 Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 10, 20266d ago S-3ASR Neutral 4/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
- Nov 10, 20266d ago Press Release Neutral 5/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $7.61 Now $7.09 −6.83% settles Feb 2
- Sep 29, 20266w ago Insider Cluster Bearish 5/10 Entry $10.71 Now $7.09 +33.80% settles Dec 24
- Sep 29, 20266w ago Press Release Bullish 6/10 Entry $10.81 Now $7.09 −34.38% settles Dec 23
- Sep 9, 20269w ago 8-K Bullish 6/10 Entry $12.09 Now $7.09 −41.36% settles Dec 3
- Sep 8, 20269w ago 8-K Neutral 2/10 Entry $12.52 Now $7.09 −43.37% settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers